Press Release

RPG LIFE SCIENCES LIMITED Regd. Off.: RPG House 463, Dr. Annie Besant Road Worli, Mumbai 400030, India Tel: +91-22-24981650 / 66606375 Fax: +91-22-24970127 RPG LIFE SCIENCES Email: info@rpglifesciences.com www.rpglifesciences.com CIN: L24232MH2007PLC169354 September 2, 2026 National Stock Exchange of India Limited BSE Limited Plot No. C/1, “G” Block, Exchange Plaza, Phiroze Jeejeebhoy Towers, Bandra Kurla Complex, Bandra (East), Dalal Street, Mumbai 400 051 Mumbai 400 001 Symbol: RPGLIFE Security Code: 532983 Dear Sirs /Madam, Sub: Press Release Please find enclosed herewith a copy of press release titled as “RPG Active Pharma acquires API business of Raghava Life Sciences to strengthen its integrated API play”. Kindly take the above on record. Thanking you, Yours Sincerely, For RPG Life Sciences Limited Rajesh Shirambekar Head- Legal & Company Secretary Encl: as above An ~»R?G Company RPG Active Pharma acquires API business of Raghava Life Sciences to strengthen its integrated API play Highwquality manufacturing asset, broad product portfolio and clear value~creation levers strengthen RPGAP's ability to capture a larger share of the growing API market • Acquisition of the API and intermediates business undertaking for consideration up to f 135 crore, subject to customary adjustments and closing conditions Adds approximately 300 KL of installed capacity in a state-of-the-art EU-GMP approved plant and a portfolio of 22 commercialized AP ls plus 7 under development, with strong regulatory approvals • RPGAP's second strategic acquisition following Actis Generics, advancing the creation of a scaled API Company across manufacturing footprint, product portfolio, customer base, synergies and export opportunities Mumbai, September 02, 2026: RPG Life Sciences Limited today announced that its wholly owned subsidiary, RPG Active Pharma Limited (RPGAP), has entered into a Business Transfer Agreement to acquire the Active Pharmaceutical Ingredients (API) and Intermediates business undertaking of Raghava Life Sciences Private Limited on a going-concern basis through a slump sale. The transaction is subject to customary closing conditions and regulatory approvals. The acquisition is the next step in RPGAP's consolidation play based on a well-planned buy-and-build strategy to bolster organic growth and create an integrated, scaled API focused organization. Following the recent acquisition of Actis Generics, this transaction broadens RPGAP's manufacturing base, product portfolio, regulatory capabilities and customer access across geographies. The consolidated organization is intended to strengthen RPGAP's participation in the growing API market through greater scale, synergies, deeper integration and focused commercial execution. A highwquality asset with significant value-unlock potential Raghava operates a modem API manufacturing facility near Hyderabad, spread across approximately 9 acres, with around 300 KL of installed capadty and a dedicated R&D set-up. The facility is WHO-GMP and EU-GMP approved with significant investment towards capacity expansion in recent years. Its established regulatory approvals, meaningful installed capacity and chemistry capabilities provide RPGAP with a high-quality manufacturing presence. The business has developed a portfolio of high-growth APls, comprising 22 commercialized products and 7 development-stage assets across diabetes, cardiovascular, CNS and other therapeutic segments. The portfolio includes commercially attractive molecules and is supported by multiple international regulatory credentials including CEP, EU Written Confirmation and KDMF approvals. This broad basket of commercialized and pipeline APls gives RPGAP access to therapy areas benefiting from strong market tailwinds. RPGAP expects to unlock value through defined synergies across this acquisition, Actis and the wider RPGAP network, including backward integration, improved capacity utilization, cost synergies and selected product transfers. Stronger business development, wider market access, deeper customer coverage and disciplined portfolio execution are poised to improve cost competitiveness, accelerate portfolio scale-up and enhance operating leverage over time. The acquisition will be funded in line with the recent equity raise announced by RPGAP. Commenting on the acquisition, Mr. Ashok Nair, Managing Director, RPG Life Sciences Limited., said: "This acquisWon marks an important addition to the RPG Active Pharma Limited consolidated organization. It brings together a high-quality manufacturing asset, a broad portfolio of commercialized AP/s, established regulatory credentials and strong customer relationships. Following Actis, it further strengthens the scale and capabilities of RPGAP and advances our strategy of building an integrated and competitive scaled AP! business. The real opportunity lies in unlocking the potential of the asset through stronger commercialization, improved capacity utilization and integrat;on across the organization. By combining these manufacturing and product capabilities with Actis' intermediate strengths and RPGAP's governance, talent and market access, we intend to build a larger presence and capture a greater share of the growing AP/ market." Commenting on the acquisition, Mr. Lohith Ponguleti, Managing Director, Raghava Life Sciences Private Limited said: "We are pleased to see Raghava Life Sdences Private Limited embark on its next phase of growth as part of RPG. Over the years, we have built a differentiated business anchored by an EU-GMP approved manufacturing facility, strong technical capabilities and a portfolio with significant growth potential. We believe RPG is well positioned to build on this foundation, accelerate expansion across domestic and international markets, and unlock the next stage of value creation for the business." Quillan Partners acted as the legal advisors, o3 Capital acted as the financial advisors and Deloitte acted as the Financial Due Diligence partner to RPG Active Pharma Limited. About RPG Life Sciences Limited RPG Life Sciences Limited is an integrated, research-based pharmaceutical company operating in domestic and international markets across branded formulations, global generics and synthetic APls. The Company develops, manufactures and markets a wide range of qua Ii ty and affordable medicines and remains focused on innovation, operational excellence and sustainable long-term growth. About RPG Active Pharma Limited RPG Active Pharma Limited is a wholly owned subsidiary of RPG Life Sciences Limited established to build a focusedAPI business with capabilities across research-led product development. manufacturing and business development. RPG Active Pharma Limited is pursuing strategic opportunities to build a diversified API organization serving domestic and international customers. Media Contact Sunaina Jairath I 98116452431 sunaina@rpg.in